ReCode Therapeutics

49 articles with ReCode Therapeutics

• ReCode Therapeutics to Present at BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines

  3/21/2023

  ReCode Therapeutics today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a panel discussion titled “Novel LNPs Targeting Diverse Tissues” at 10:00 a.m. ET on Tuesday, March 28, 2023 at the virtual BMO Biopharma Spotlight Series.

• ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia

  3/15/2023

  ReCode Therapeutics announced today that the first healthy volunteer participants have been dosed in a Phase 1 clinical trial of RCT1100, a first-in-class, mRNA-based genetic medicine for the treatment of people with primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene.

• Recode Therapeutics Expands Leadership Team with Appointment of April Loui as Senior Vice President of Quality and CMC Regulatory Affairs

  2/1/2023

  ReCode Therapeutics announced today the appointment of April Loui, MBA, CSSBB, as senior vice president of quality and chemical, manufacturing and controls (CMC) regulatory affairs.

• ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy

  1/10/2023

  ReCode Therapeutics announced today that it will receive a strategic investment from the Cystic Fibrosis Foundation (CF Foundation) to develop ReCode’s inhaled mRNA-based therapeutic for people with cystic fibrosis (CF), including those with genotypes that do not respond to approved CFTR modulators.

• ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform

  1/9/2023

  ReCode Therapeutics announced today it has signed a multi-year research collaboration and option agreement with Asklepios BioPharmaceutical, Inc. (AskBio).

• AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform

  1/9/2023

  Asklepios BioPharmaceutical, Inc. announced today that it has signed a multi-year research collaboration and option agreement with ReCode Therapeutics.

• ReCode Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  ReCode Therapeutics today announced that Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics, will present a company overview at 9:00 a.m. PT on Tuesday, January 10, 2023 at the 41st Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA.

• ReCode Therapeutics Appoints Trisha Millican to Board of Directors

  12/1/2022

  ReCode Therapeutics announced today the appointment of Patricia “Trisha” Millican to the company’s Board of Directors.

• ReCode Therapeutics to Present at Upcoming Investor Conferences in 2022

  11/22/2022

  ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences.

• ReCode Therapeutics Establishes Scientific Advisory Board

  11/14/2022

  ReCode Therapeutics announced today the formation of the company's scientific advisory board (SAB).

• ReCode Therapeutics to Participate in Upcoming November 2022 Investor Conferences

  11/2/2022

  ReCode Therapeutics announced that Company leadership will participate in two upcoming investor conferences in November.

• ReCode Therapeutics to Participate in Upcoming October Investor Conferences

  9/29/2022

  ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in October.

• ReCode Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit

  9/22/2022

  ReCode Therapeutics today announced that David Lockhart, Ph.D, President and Chief Scientific Officer of ReCode Therapeutics, will present a company overview at 8:00 a.m. ET on Thursday, September 29, 2022 at the upcoming Jefferies Cell and Genetic Medicine Summit being held in New York.

• Fierce Biotech Names ReCode Therapeutics as One of its “Fierce 15” Biotech Companies of 2022

  9/12/2022

  ReCode Therapeutics , a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

• ReCode Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

  9/6/2022

  ReCode Therapeutics, announced today that Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics, will present a corporate overview at 8:00 a.m. ET on Tuesday, September 13th at the upcoming Morgan Stanley 20th Annual Global Healthcare Conference being held in New York, NY.

• ReCode Therapeutics to Participate in Upcoming July Investor Conferences

  7/6/2022

  ReCode Therapeutics , a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Company leadership will participate in two upcoming investor conferences in July.

• 

  Money on the Move: ReCode, MiroBio & More Target Technology

  6/29/2022

  This week money went towards more advanced rounds of financing for drugs and technology that have already shown a lot of promises.

• ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M

  6/29/2022

  ReCode Therapeutics announced the close of a Series B extension financing round, co-led by new investors, Leaps by Bayer, the impact investment unit of Bayer AG, AyurMaya, an affiliate of Matrix Capital Management, and with participation from Amgen Ventures.

• ReCode Therapeutics to Present at Jefferies Healthcare Conference

  6/3/2022

  ReCode Therapeutics , a biopharmaceutical company powering the next wave of genetic medicines through superior delivery, today announced that David Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics will present a corporate overview on Friday, June 10th from 11:00 - 11:25 a.m. ET at the Jefferies Healthcare Conference being held in New York, NY from June 8-10, 2022.

• ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference

  5/15/2022

  ReCode Therapeutics, a biopharmaceutical company powering the next wave of genetic medicines through superior delivery presented new preclinical data from the company’s inhaled mRNA-based molecular therapy program for the treatment of primary ciliary dyskinesia in three posters at the American Thoracic Society 2022 International Conference, taking place May 13-18, 2022 in San Francisco.